Complaints Outcomes

Search

Search Results

Search Again
Pharmacist Registrant 36 (Jun 10, 2018)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend her registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 21 (Jun 10, 2018)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached a new Agreement with the pharmacist registrant to amend certain terms in his Agreement of May 1, 2017. The pharmacist registrant is now no longer subject to medical monitoring. All other limits and conditions will remain as part of the new Agreement for a minimum of six months, after which the registrant’s medical condition may be reassessed. The registrant has also agreed to begin a gradual return to work. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition.


May 11, 2017
(June 10, 2018 - Limits and Conditions Updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 27, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to his routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of 12 months;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The Agreement will remain in place for a minimum of 12 months from the date of execution of the Agreement, following which the Registrant may submit information or documentation, including independent medical assessments, to support removing any or all of the above limits and conditions. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


July 27, 2016
(May 1, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective July 27, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.


February 27, 2015
(July 27, 2016 – Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 23, 2014. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to his routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of 3 years;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The agreement will remain in place for a minimum of three years from the date of execution of the Agreement, following which the Registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


JULY 23, 2014
(FEBRUARY 27, 2015 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective July 23, 2014. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.

Pharmacist Registrant 23 (May 26, 2018)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached a new Agreement with the pharmacist registrant to amend certain terms in his Agreement of March 6, 2017. The pharmacist registrant is now no longer subject to limits and conditions relating to working alone and the handling, counting, and dispensing of narcotic, controlled, opioid and sedative drugs. All other limits and conditions will remain as part of the new Agreement.


March 6, 2017
(May 26, 2018 - Limits and conditions updated)

The Inquiry Committee, pursuant to Section 36 of the Health Profession Act, has reached a new revised agreement with the pharmacist registrant, whereby the registrant consented to undertakings that include, but are not limited to:

  1. Strictly adhering to registrant’s routine medical monitoring program with the institution currently involved in registrant’s care and remaining on the monitoring program for a period of 5 years;

  2. Informing all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to the Agreement;

  3. Registrant will not work alone in a pharmacy setting, meaning that registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with registrant at all times;

  4. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  5. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  6. The registrant will not physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like). In dispensing such prescriptions, the registrant will only be involved in the intake, data entry, computer processing, final check and pharmacist/patient counseling in accordance with the Health Professions Act, Bylaws; for a period of one (1) year, after which this term will be reassessed.

  7. The registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like); for a period of one (1) year, after which this term will be reassessed.

  8. The registrant will not be restricted from acting in the role in registrant’s practice as pharmacy manager or director but he will be restricted from acting in the role in registrant’s practice as a preceptor;

  9. The registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

This agreement will remain in place for a minimum of four years from March 6, 2017, following which the registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


JUNE 23, 2016
(MARCH 6, 2017 – LIMITS AND CONDITIONS UPDATED)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on December 18, 2015. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to Registrant’s routine medical monitoring program with the institution currently involved in Registrant’s care and remaining on the monitoring program for a period of 5 years;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. For one (1) year, Registrant will not physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like). In dispensing such prescriptions, the Registrant will only be involved in the intake, data entry, computer processing, final check and pharmacist/patient counseling in accordance with the Health Professions Act, Bylaws; after which this term will be reassessed.

  8. For one (1) year, Registrant will document the steps taken for dispensing narcotic and controlled drugs and ensure that Registrant’s peer co-signs the document to show compliance with the restrictions set forth in item 7; after which this term will be reassessed.

  9. For one (1) year, Registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like); after which this term will be reassessed.

  10. The Registrant will be restricted from acting in the following roles in Registrant’s practice:
    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  11. The Registrant will notify the College, in writing or via e-mail, of:
    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The agreement will remain in place for a minimum of five years from the date of execution of the Agreement, following which the Registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


DECEMBER 18, 2015
(JUNE 23, 2016 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist effective December 18, 2015. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The registrant's name has been withheld, pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 16 (May 24, 2018)

Pharmacist registrant 16 has satisfied the terms of an agreement reached with the Inquiry Committee dated May 24, 2013.  Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


May 27, 2013
(May 24, 2018 – Limits and conditions removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on April 17, 2013. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with pharmacist registrant in which she was asked to consent to certain undertakings. This agreement remains in effect until May 24, 2018. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act


April 27, 2013
(MAY 27, 2013 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend her registration as a pharmacist for an indefinite period pending further disposition by the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Ali, Mir Rashid (May 14, 2018)

Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with Mir Rashid Ali (the “Registrant”) to suspend his registration as a pharmacist for 90 consecutive days commencing July 1, 2018.

The Registrant acknowledged that between January 1, 2013 and May 19, 2015, while he was a director and pharmacist at two different pharmacies and pharmacy manager of one of these pharmacies, many prescriptions at both pharmacies were “late-filed”, meaning that dispensing records for these prescriptions were created on dates later than the dates on which the drugs in question were actually dispensed, contrary to section 35(1) (then s. 21(1)) of the Bylaws to the Pharmacy Operations and Drug Scheduling Act.

The Registrant also acknowledged that during the time period he was pharmacy manager at one pharmacy, many claims were billed on PharmaNet for patients who according to the provincial Discharge Abstract Databased had been admitted to hospital at time of claim, suggesting that these patients may not have received the supplies claimed.

The Inquiry Committee was concerned that the Registrant had previously consented to remedial undertakings to fully comply with legislated practice standards, and he had not done so for this current matter. The Inquiry Committee therefore considered this constituted a “serious matter” pursuant to section 26 of the Health Professions Act, and that the Registrant required serious remediation and deterrence in order to come into compliance.

Pursuant to his Agreement, the Registrant also consented to the following:

  • To not be a pharmacy manager and preceptor for a period of two years from the date that his suspension ends;
  • To pay a $7,500.00 fine;
  • To successfully pass the College’s Jurisprudence Exam;
  • To appear before the Inquiry Committee for a verbal reprimand; and
  • A Letter of Reprimand on his registration record.

The Inquiry Committee considers this Agreement necessary to protect the public, as well as send a clear message of deterrence to the profession. 

Lam, Miguel Angel (May 6, 2018)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached an Agreement with former registrant Mr. Miguel Lam. He has resigned from registration with the College and has undertaken to not apply for registration or reinstatement of registration to the College and/or to apply for registration in any capacity by a governing body for pharmacy in another province or foreign jurisdiction in the future. He has also agreed to pay a $10,000.00 fine.

After an investigation into his pharmacy practice, the Inquiry Committee advised that while Mr. Lam was a registrant and pharmacy manager of a pharmacy, he did not maintain a standard of practice of the pharmacy profession and did not uphold the relevant provincial and federal legislation with respect to the inventory management, record keeping, reporting of losses, and dispensing of narcotic, controlled, and/or benzodiazepine drugs.

The Inquiry Committee considered that the Mr. Lam’s conduct constituted professional misconduct, a serious matter pursuant to section 26 of the Health Professions Act. On the basis of his undertakings in the Agreement, the Inquiry Committee has agreed to not proceed further with this matter unless and until he seeks reinstatement of his registration. The Inquiry Committee considers his undertakings in the Agreement to be sufficient to protect the public and that the publication of this information will send a clear message of deterrence to the profession.


May 9, 2017
(May 6, 2018 – Limits and Conditions Updated, Registrant Resigned)

The Inquiry Committee, pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant Miguel Angel Lam, pending completion of an investigation of his pharmacy practice. Until further notice, Mr. Lam has the following limits and conditions on his practice:

  1. Effective May 23, 2017, he will be restricted from acting as a manager of any pharmacy. 
  2. Effective May 9, 2017, he will be restricted from doing the following in relation to narcotic and controlled drugs and substances:
    1. Placing and receiving orders; and
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders.

As the pharmacy manager of a pharmacy, Mr. Lam has not been fulfilling his responsibilities to operate a pharmacy that meets legislative and practice standards. He has not kept accurate records regarding all purchases and sales of narcotic and controlled drugs. He has not established and/or enforced policies and procedures for inventory management and security and storage of narcotic and controlled drugs, enabling a large quantity of narcotic and controlled drugs at the pharmacy to be unaccounted for, causing potential harm to the public.

Pharmacist Registrant 13 (Apr 19, 2018)

Pharmacist Registrant 13 has satisfied the terms of an agreement reached with the Inquiry Committee dated April 18, 2013. Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.


April 18, 2013
(April 19, 2018 - Limits and Conditions Removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on December 5, 2012. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with pharmacist registrant to place limits and/or conditions on his registration as a full pharmacist, effective April 18, 2013. This agreement remains in effect until April 18, 2018. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


December 5, 2012
(April 18, 2013 – Registration reinstated) 

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further disposition by the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Li, Jin Tong (Apr 13, 2018)
 

Jin Tong (Tom) Li has completed a term of suspension which ended on April 13, 2018, and his registration as a pharmacist has been reinstated. The registrant is limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years commencing April 14, 2018.


October 20, 2016
(April 13, 2018 – Registration reinstated)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with Jin Tong (Tom) Li (the “Registrant”) to suspend his registration as a pharmacist for 540 consecutive days, from October 20, 2016 to April 13, 2018.

The Registrant acknowledged that between January 1, 2014 and December 22, 2014, he submitted fraudulent claims to PharmaCare over the PharmaNet system on over 2400 occasions. On all occasions, the Registrant had billed a high dollar value medication on PharmaNet, then reversed the medication to manipulate PharmaCare deductibles and to effectively allow patients to receive financial benefits from PharmaCare to which they were not entitled.

The Registrant also acknowledged that between January 1, 2013 and December 31, 2014, he had been the dispensing pharmacist and/or pharmacy manager responsible for multiple practice deficiencies including dispensing quantities in large excess of what had been authorized, dispensing from invalid prescriptions, dispensing from incomplete prescriptions, dispensing prescriptions under the incorrect prescriber’s name, dispensing incorrect medications, processing blood glucose test strips on PharmaNet in large excess of what could be accounted for by wholesaler invoices, and not keeping complete patient records and prescription documentation.

Prior to reinstatement of his registration following the suspension period, the Registrant will be required to:

  • thoroughly review relevant legislative requirements and to sign a Declaration acknowledging his understanding of and compliance with the legislative requirements;
  • to meet with the Inquiry Committee to discuss his reflections on his conduct and what he has learned; and
  • to complete an ethics course at his own expense.

The Registrant will also be limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years from the date that his suspension ends (commencing April 14, 2018).

The Inquiry Committee considers this agreement necessary to protect the public, as well as send a clear message to the profession that the College does not tolerate this type of conduct. 

Pharmacist Registrant 35 (Mar 6, 2018)

The Inquiry Committee, pursuant to Section 32.2(4)(b)(ii) of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further disposition of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Berra, Patrizia (Feb 22, 2018)

Patrizia Berra has completed a term of suspension which ended on February 21, 2018, and her registration as a pharmacist has been reinstated as of February 22, 2018. 


December 18, 2017
(February 22, 2018 – Registration reinstated)

Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) reached an agreement by consent with pharmacist registrant Patrizia Berra (the “Registrant”) to suspend her registration as a pharmacist for a period of one month from January 22, 2018 to February 21, 2018.

A member of the public obtained a printout of her PharmaNet record and discovered that the Registrant accessed her PharmaNet record. The Registrant admitted that she did not dispense a medication, provide patient counselling or evaluate a patient’s drug usage when she accessed the patient’s PharmaNet record, and that the access was without consent.

Following investigation, the Inquiry Committee determined that the Registrant inappropriately accessed a PharmaNet record for reasons unrelated to health care and without consent, in contravention of sections 21(2) and 21(3) of the Bylaws to the Pharmacy Operations and Drug Scheduling Act, section 71 of the Bylaws to the Health Professions Act, and Standard 4 of the Code of Ethics.

The Inquiry Committee found that this constitutes a “serious matter” and that inappropriate access of personal health information compromises the public’s trust in individual registrants and the pharmacy profession as a whole. Previous complaints considered by the Inquiry Committee have found that even inadvertent and innocuous inappropriate access by a registrant is sufficient for an onerous disposition.

Therefore, the Inquiry Committee and the Registrant agree that the Registrant shall submit a fine of $1,000, suspend her registration for a period of one month, and thereafter appear before a panel of the Inquiry Committee for a verbal reprimand. A letter of reprimand shall be placed on the College register as a permanent record and the College may disclose its contents in response to inquiries regarding the status of the Registrant’s registration. The Inquiry Committee considers this agreement necessary to protect the public.

Pages